Exciting News! Pheiron has entered a strategic collaboration with Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Co., Ltd to accelerate the discovery and development of RNA-based therapeutics with evidence from large human populations generated through PheironGPS. This partnership will bring advanced human evidence to Ribo’s focus on cardiometabolic diseases, helping to: ▶ Prioritize therapeutic targets ▶ Pinpoint causal disease mechanisms ▶ Optimize patient stratification for clinical development We will work closely with Ribo’s stellar scientists to enhance the probability of success in developing next-generation therapies for unmet medical needs. Stay tuned for more updates on this exciting journey! More information: https://lnkd.in/eGPyGYjY https://lnkd.in/eC4vdj27 PheironGPS: https://lnkd.in/e7q52qWP #GeneticEvidence #PopulationCohorts #Phenotyping #RNATherapeutics #AIbiomarker #AIinDrugDevelopment #CardiometabolicDiseases #PheironGPS #Biotech #PharmaInnovation
Info
We radically improve the probability of success in drug development by getting right what really matters: human evidence to back the target and prognostic disease signatures to define the population.
- Website
-
pheiron.com
Externer Link zu Pheiron
- Branche
- Biotechnologieforschung
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Berlin
- Art
- Privatunternehmen
- Gegründet
- 2023
Orte
-
Primär
Berlin, DE
Beschäftigte von Pheiron
Updates
-
Pheiron hat dies direkt geteilt
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) have entered a strategic partnership with Pheiron to leverage its cutting-edge AI platform, PheironGPS, in Ribo’s discovery and development of RNA-based therapeutics. This collaboration aims to enhance Ribo’s target discovery capacity in cardiometabolic diseases by integrating advanced human evidence generated through Pheiron’s AI technology. PheironGPS systematically integrates human multi-omic data at scale to pinpoint biological mechanisms and drive actionable insights on targets and patient populations. This collaboration will establish a strong scientific connection between therapeutic targets and disease causality, offering unprecedented guidance for the clinical development of Ribo’s RNA-based therapeutics. “We can now access multi-omic information from both general and specific patient populations. We are delighted to collaborate with the highly skilled scientists at Pheiron. Their proprietary AI algorithms, combined with our experienced scientists and drug developers, will help unravel complex patho-physiological networks. This collaboration will increase our success rate in discovering novel biology and disease pathways linked to unmet medical needs in the cardiometabolic area”, says Li-Ming Gan, CEO of Ribocure Pharmaceuticals AB and co-CEO of Suzhou Ribo Life Science, Ltd “Human population-scale datasets are transforming how we understand and treat disease. PheironGPS is bringing human evidence to the forefront of decision-making, delivering clarity on disease mechanisms and patient populations that can significantly raise the probability of success in clinical development. We are delighted to collaborate with Ribo and shape the next generation of RNA therapeutics with evidence from large human populations”, continues Thore Buergel, CEO Pheiron. Pheiron Suzhou Ribo Life Science Co., Ltd #siRNA #cardiometabolicdiseases #GeneticEvidence #PopulationCohorts #Phenotyping #RNATherapeutics #AIbiomarker #AIinDrugDevelopment #PheironGPS
-
Pheiron hat dies direkt geteilt
We are at the brink of a fundamental shift to transform clinical research and development. This is due to the emergence of two trends that together create conditions ripe for scientific discovery: - Real-world data (RWD): The availability of large, multimodal clinical datasets - AI: The proliferation of clinical AI tools to extract insights from these datasets To assess the impact of this combination we asked the question below, with the help of our friends at Pheiron and the incredible work of the Dandelion team (thank you, all of you). Can GLP-1s reduce the risk of heart attacks and strokes among those who do not yet suffer from severe cardiovascular disease? The goal was to go beyond what the Novo Nordisk SELECT trial had previously done when they studied people that had recently had cardiac events. Here are our 4 key findings: 1. Expanded population: GLP-1s may serve as primary prevention for obese patients with mild or moderate CVD – almost 40 million additional patients in the U.S. alone (this only reflects patients with ECGs so the number could be nearer 100 million). 2. Impact: Our study found a statistically significant 15-20% reduction of Major Adverse Cardiac Events (MACE) risk using AI. This is in line with MACE incidence results observed in a similar past clinical trial (17,604 participants and 5 years). 3. Accelerated Signal: Using AI, we detected decreased risk just 1.7 years after GLP-1 initiation (as opposed to the 3.3 year study period in the Novo Nordisk SELECT trial). AI enables faster the signal by predicting cardiovascular risk, rather than analyzing actual adverse events. 4. Reduced Trial Size: AI may decrease trial duration and required recruitment size by more accurately identifying appropriate trial participants. This was all covered by Fierce Healthcare and CNN. Thank you to Deidre McPhillips and Emma Beavins If you wish to read our white paper that these findings come from, please follow the link in the comments to download it. We genuinely hope this is the start of opening up the floodgates to more people working out how to utilise AI in order to reduce the time and expense of drug development, whilst increasing the accuracy and effectiveness of our trial process. With many thanks to: Shivaani Prakash, MSc, PhD, Ana-Vanessa “AV” Ploumpis, Gonzalo Hernandez, Jamie Dermon, MD, CPHQ, Ross Bierbryer, Isaac Moshe, Luke Sagers, Nick Burke, Kiko Wemmer, Maxence Frenette, Owen Kasozi, Manqing L., Nicholas Gossen, Richard Y., Matthew Stewart, PhD, Mathilde Williams, Balazs Lengyel, MD, Nick Znajkowski, Mara Alexeev, Sofia (Becerra) Van Dusen, Nicholas Shea, Seema Sood, Jason Ma, Armend Cobovic, Thore Buergel, Jakob Steinfeldt, MD, Dave Clarke, Steven Gipstein M.D., Sharp HealthCare, Texas Health Resources Sanford Health and of course, Ziad Obermeyer, Sendhil Mullainathan and Niyum Gandhi.
Dandelion Health launches AI marketplace for model validation, use in clinical trials
fiercehealthcare.com
-
We are very excited to see this out. A strong demonstration of how AI-biomarkers and real world data are going to transform clinical research. #AI #phenotyping #multiomics #RWD
Breaking news - today we launched results from a large study that uncovered how GLP-1 medications may help prevent cardiovascular disease for 44M previously unstudied U.S. patients. The study was conducted using a validated AI algorithm from Pheiron, accessible on our brand new Clinical AI Marketplace, which also launched today. To learn more about the mission-critical work we’re doing to help life sciences companies accelerate clinical development & commercialization at a fraction of the typical time & cost, check out this story from Deidre with CNN: https://lnkd.in/g5F-Dqxi To download the full research whitepaper, see the link in the comments. #GLPs #clinicaltrials #realworlddata #AI #digitalhealth #pharma
GLP-1 drugs could help prevent 34,000 heart attacks and strokes in the US each year, research suggests | CNN
amp.cnn.com
-
Despite decades of medical research, clinicians and researchers often struggle to predict who will develop diseases or face complications. This uncertainty directly affects drug development: clinical trials are often inefficient, lacking reliable biomarkers to identify the right populations and track therapeutic outcomes. At Pheiron, we use AI to integrate multi-omic data and accurately capture disease pathophysiology in AI-driven biomarkers that reflect the natural progression of disease. One key application of our AI-biomarkers is in enhancing the evidence generated from RCTs and real-world observational studies. Here we validated and applied one of our AI-biomarkers predicting cardiovascular risk from 12-lead ECGs with Dandelion Health in a study investigating cardioprotective benefits of GLP-1's. We found: 1️⃣ GLP-1s could benefit a much broader population than initially tested in the SELECT trial 2️⃣ Each year of GLP-1 use is associated with a 4% reduction in percentile risk of myocardial infarction and a 3.6% reduction in percentile risk of stroke 3️⃣ ~44M additional patients may benefit from a GLP-1 in the US alone, which could prevent ~34K strokes and MIs annually Read more in our white paper, linked below and reach out if you would like to learn more. Pre-print coming soon! White paper: https://lnkd.in/eB5w77TC
Assessing GLP-1’s Cardioprotective Benefits with an ECG-based AI-Biomarker
pheiron.com
-
Pheiron hat dies direkt geteilt
Our August issue is online! Read about marine biotechnology, microbiome-integrated cities (Jake M. Robinson), the nitroplast organelle, engineering cyanobacteria (Pratyoosh Shukla), urine-derived precision medicine (Wake Forest Institute for Regenerative Medicine), RNA-guided genome engineering, bacterial biocontrol agents, cryptography in synthetic DNA (Jean Peccoud), CRISPR activation screens (Greg Neely), pure cultures in microbial electrosynthesis, genome-scale synthetic biology (Byung-Kwan Cho), and large-scale data for drug development (Pheiron). https://lnkd.in/eBMP_eZn
-
Pheiron hat dies direkt geteilt
Episode 143 of The Genetics Podcast is available now! 🚀 This week, Patrick Short is joined by Jakob Steinfeldt, MD, Co-Founder and Chief Scientific Officer at Pheiron and Honorary Research Fellow at UCL. Tune in to discover: 🎯 How Pheiron is building a GPS for #DrugDevelopment, helping researchers identify highly-relevant patients and drug targets 💻 Why there’s so much potential in #MachineLearning and human data 🌏 What inspired Jakob to make the move from doctor and academic, to start-up co-founder And much more! Listen by following the link below 👇 or search ‘The Genetics Podcast’ on your go-to podcast platform. 🎧 https://pod.fo/e/253a3a 📽️ https://lnkd.in/eJqPdHvh #SanoGenetics #PrecisionMedicine #BigData #TheGeneticsPodcast
-
Pheiron hat dies direkt geteilt
Thanks, Patrick Short, for hosting me on #TheGeneticsPodcast! It was great to share what we are building at Pheiron!
Episode 143 of The Genetics Podcast is available now! 🚀 This week, Patrick Short is joined by Jakob Steinfeldt, MD, Co-Founder and Chief Scientific Officer at Pheiron and Honorary Research Fellow at UCL. Tune in to discover: 🎯 How Pheiron is building a GPS for #DrugDevelopment, helping researchers identify highly-relevant patients and drug targets 💻 Why there’s so much potential in #MachineLearning and human data 🌏 What inspired Jakob to make the move from doctor and academic, to start-up co-founder And much more! Listen by following the link below 👇 or search ‘The Genetics Podcast’ on your go-to podcast platform. 🎧 https://pod.fo/e/253a3a 📽️ https://lnkd.in/eJqPdHvh #SanoGenetics #PrecisionMedicine #BigData #TheGeneticsPodcast
-
How can we avoid clinical stage failures and get drugs to patients faster? Our Co-founder and Chief Scientific Officer Jakob Steinfeldt, MD, sat down with Sano Genetics CEO Patrick Short and shared his thoughts on the Genetics Podcast. Listen in to learn more about how we use AI to characterize disease and unleash the power of human genetics, with immediate impact on clinical success rates! Reach out if you'd like to learn more -- or just to discuss science! Podcast episode available via Web: https://lnkd.in/emQnuR6R Apple Podcasts: https://lnkd.in/eVbGSgP5 Spotify: https://lnkd.in/ebtMTp3x #genetics #phenotyping #humanevidence #humangenetics #innovation #AIDD #clinicalsuccess #geneticspodcast #thegeneticspodcast
-
🌟 Paper Alert: Founding Geneticist Lena Kaisinger's latest study on puberty genetics is out in Nature Genetics! The large team of researchers from the MRC Epidemiology Unit at University of Cambridge, identified genetic signals affecting pubertal timing, an important risk factor for later-life diseases. Congratulations Lena, we are proud to have you in the team! Full article: https://lnkd.in/ehncpzQD Original post: https://lnkd.in/ekf-SqHX #genetics #humangenetics #pheiron #teampheiron Team Pheiron
Excited to share that my latest research paper, “Understanding the genetic complexity of puberty timing across the allele frequency spectrum”, has been published in Nature Genetics. This work, involving hundreds of collaborators across the globe was a significant part of my PhD at the MRC Epidemiology Unit, University of Cambridge, alongside Katherine Kentistou and my supervisors John Perry and Ken Ong. Early puberty is increasingly common and is linked to an increased risk of later-life diseases. Our study, the largest on puberty genetics to date, analyzed data from over 800,000 participants, identifying more than 1,000 common genetic signals and six rare variants affecting pubertal timing. Notably, about half of the genetic variants influencing puberty timing do so indirectly by accelerating childhood weight gain. A summary can be found here: https://lnkd.in/dK2i83By. And for those interested, the full paper is available here: https://lnkd.in/d-i6KE_X.
Largest ever genetic study of age of puberty in girls shows links with weight gain
cam.ac.uk